Angiotensin II receptor blocker

Telmisartan

The US label gives telmisartan's terminal elimination half-life as approximately 24 hours, which matches the app's figure of 24 hours.1

Strong evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Telmisartan after one dose: 50% at ~24 h, 25% at 48 h, 12.5% at 72 h.

Drawn from the half-life in the app's model, ~24 h. The model's figures

Telmisartan is an angiotensin II receptor blocker (ARB); the US label cited here is a generic telmisartan tablets label from Alembic Pharmaceuticals.1 It lists two uses: hypertension, and reducing the risk of myocardial infarction, stroke or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitors.1

The label gives 1998 as the initial US approval year, and the European Medicines Agency's product information for Micardis gives 16 December 1998 as the date of first authorisation.1,2 The app grades the evidence for telmisartan as strong, and its own notes describe off-label metabolic interest, which the human studies below test.

2

How it works

The label states that telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking angiotensin II binding to the AT1 receptor, and that its affinity for AT1 is much greater than for AT2.1 Because telmisartan does not inhibit ACE (kininase II), the label states, it does not affect the response to bradykinin, and "Whether this difference has clinical relevance is not yet known".1 In normal volunteers, a dose of 80 mg inhibited the pressor response to an intravenous angiotensin II infusion by about 90% at peak plasma concentrations, with approximately 40% inhibition persisting for 24 hours; the app lists a duration of 24 hours.1 Hsueh and colleagues describe telmisartan as a partial agonist of peroxisome proliferator-activated receptor-gamma (PPAR-gamma), the basis of the off-label metabolic interest.3 The same authors conclude from their own trial that effects of telmisartan on insulin resistance probably cannot be attributed to a significant degree to that partial agonism, while stating that the results do not unequivocally exclude PPAR-gamma agonism as a contributing mechanism.3

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~24 h
Bioavailability
45%
Typical dose
20–80 mg/day
Route
Oral
Time to peak
~1 h

The second column of the table holds the app's own figures, shown beside what the US label and the European product information report.

Table 3.1Half-life and pharmacokinetics7 rows
ParameterApp's figureReported in the sources
Half-life~24 hTerminal elimination half-life of approximately 24 hours on the US label, which also states that terminal half-life and total clearance appear to be independent of dose; more than 20 hours in the European product information1,2
Bioavailability45%Dose dependent on the US label, 42% at 40 mg and 58% at 160 mg; a mean absolute bioavailability of about 50% in the European product information1,2
Time to peak~1 hPeak concentrations reached 0.5 to 1 hour after dosing on the US label; trough concentrations with once-daily dosing about 10% to 25% of peak1
Volume of distributionNot listed by the appAbout 500 L on the US label and in the European product information1,2
Metabolism and eliminationGlucuronidation, mostly biliary (the app's notes)Conjugation to a pharmacologically inactive acyl glucuronide; cytochrome P450 isoenzymes not involved in metabolism, with in vitro inhibition of CYP2C19 the stated exception; most of the dose eliminated unchanged in feces via biliary excretion, with minute amounts in urine1
Accumulation and kidney functionNo renal accumulation (the app's notes)Accumulation index in plasma of 1.5 to 2 on repeated once-daily dosing on the US label, which states no dosage adjustment is necessary with decreased renal function and that telmisartan is not dialyzable; no evidence of clinically relevant accumulation at the labelled dose in the European product information1,2
Sex and liverNot listed by the appPlasma concentrations generally 2 to 3 times higher in females than in males; in hepatic insufficiency plasma concentrations increased and absolute bioavailability approaches 100%1

Level over 6 weeks

Interval between doses

Level, as a share of the peak after one 100 mg dose

As studied: once daily1.

An illustration from a pharmacokinetic model using a half-life of 24 hours. It is not a measured level or a suggested dose.

4

Human studies

The US label's outcome section rests on ONTARGET, which it says enrolled 25,620 patients, and TRANSCEND, which it says enrolled 5926.1

Table 4.1Human studies6 rows
Study and yearDesignPeopleDose and lengthMain result
ONTARGET Investigators (Yusuf), New England Journal of Medicine 20084Double-blind randomised comparison of ramipril, telmisartan and both; sponsor Boehringer Ingelheim4,10Patients with vascular disease or high-risk diabetes without heart failure; 8576 on ramipril, 8542 on telmisartan, 8502 on both4Ramipril 10 mg/day, telmisartan 80 mg/day or both; median follow-up 56 months4Primary outcome in 1423 (16.7%) on telmisartan and 1412 (16.5%) on ramipril, relative risk 1.01 (95% CI 0.94 to 1.09); 1386 (16.3%) on the combination; cough 1.1% vs 4.2%, angioedema 0.1% vs 0.3%, hypotensive symptoms 2.6% vs 1.7% (telmisartan vs ramipril); renal dysfunction 13.5% vs 10.2% (combination vs ramipril)4
TRANSCEND Investigators (Yusuf), Lancet 20085Randomised comparison with placebo; funded by Boehringer Ingelheim55926 patients with cardiovascular disease or diabetes with end-organ damage who were intolerant to ACE inhibitors5Telmisartan 80 mg/day (n=2954) or placebo (n=2972); median follow-up 56 months5Primary outcome 465 (15.7%) vs 504 (17.0%), hazard ratio 0.92 (95% CI 0.81-1.05, p=0.216); cardiovascular death, myocardial infarction or stroke 384 (13.0%) vs 440 (14.8%), p=0.048 unadjusted and p=0.068 after adjustment; permanent discontinuation of study medication 639 (21.6%) vs 705 (23.8%)5
Hsueh and colleagues, Journal of Clinical Hypertension 20103Phase 2, double-blind, placebo-controlled, parallel-group; supported by Boehringer Ingelheim3,11138 overweight or obese adults without diabetes or hypertension; 128 completed3Telmisartan 80 mg/day for 2 weeks then 160 mg/day for 14 weeks, or placebo; 16 weeks3No significant difference in the change from baseline in the insulin sensitivity index from oral glucose tolerance testing (adjusted mean change 0.30 placebo vs 0.19 telmisartan, P=.8217) or in glucose area under the curve; no significant between-group differences in glucose metabolism or lipoproteins3
Wohl and colleagues, European Journal of Endocrinology 20106Double-blind randomised crossover; funding not stated in the saved record612 patients with impaired fasting glucose and metabolic syndrome6Telmisartan 160 mg/day or placebo for 3 weeks each, 2-week washout6Fasting plasma glucose lower after telmisartan than placebo (P<0.05); no differences in insulin sensitivity or substrate utilization on a hyperinsulinemic euglycemic clamp; no differences in basal adiponectin, resistin and tumour necrosis factor alpha, but an increase in basal leptin, and increased insulin-stimulated adiponectin, leptin and resistin with decreased tumour necrosis factor alpha during the clamp6
Chetty and colleagues, Blood Pressure 20147Double-blind randomised placebo-controlled; funding not stated in the saved record795 adults with abdominal obesity (body mass index 30 kg/m2 or more and a larger waist circumference)7Telmisartan 80 mg/day for 4 weeks then 160 mg/day, or placebo; 24 weeks7No significant effect on muscle fat (IMCL) or liver fat; body composition, lipid and glucose profiles, insulin sensitivity and adiponectin unaffected; beta-cell function (insulinogenic index) improved, p = 0.037
Fogari and colleagues, Hormone and Metabolic Research 20098Randomised crossover against eprosartan with placebo periods; funding not stated in the saved record850 overweight outpatients aged 41-65 with mild to moderate hypertension8Telmisartan 80 mg or eprosartan 600 mg for 8 weeks each8Glucose infusion rate on a clamp rose with telmisartan (2.25+/-0.61 micromol/min/kg, p<0.05 vs placebo) but not eprosartan (0.25+/-0.14, p=ns); total cholesterol -9.9 mg/dl and LDL-C -8.8 mg/dl with telmisartan only; no change in fasting glucose or insulin with either8

The trials disagree on insulin sensitivity: Fogari and colleagues report a higher glucose infusion rate with telmisartan, while Hsueh, Wohl and Chetty and colleagues report no difference in insulin sensitivity.8,3,6,7 A search of PubMed for telmisartan and insulin sensitivity in randomised trials returned 85 records, among them meta-analyses; the four trials above are the ones compared here, not a complete review.

Mouse lifespan study (not a human study)

Korstanje and colleagues, for the National Institute on Aging Interventions Testing Program (GeroScience, 2026), tested an atorvastatin-telmisartan combination ("Atortel") in genetically heterogeneous UM-HET3 mice at three sites, in the diet from 7 months of age at target doses of 120 ppm atorvastatin and 30 ppm telmisartan (achieved 48 and 27 ppm).9 Telmisartan was given only with atorvastatin, so the result belongs to the combination and not to telmisartan alone.9 Pooled median lifespan was 847 days in 153 treated males against 813 in 300 controls (+4.18%, log-rank p 0.644) and 869 days in 132 treated females against 903 in 272 controls (-3.82%, p 0.154).9 The authors write that "no new compounds (Mife, Atortel, Meth, and Pio) showed a significant increase in lifespan", and note that their p-values "are not adjusted for multiple comparisons" and that control females at one site had an unusually long median lifespan with no obvious explanation.9 With the site whose control females were unusually long-lived excluded (UM and UT only), the Atortel females had a median lifespan of 866 days against 855 in 180 controls (+1.23%, log-rank p 0.708), and females on Atortel had significantly lower body weights than controls.9 The work was funded in part by National Institute on Aging grants.9

Deeper analysis: ONTARGET

Yusuf and colleagues for the ONTARGET Investigators, at the Population Health Research Institute, McMaster University and Hamilton Health Sciences in Hamilton, Canada, reported the trial in the New England Journal of Medicine in 2008.4 The ClinicalTrials.gov entry names Boehringer Ingelheim as lead sponsor, lists ONTARGET and TRANSCEND under one record with an actual enrolment of 31546, and states as a primary aim that telmisartan 80 mg daily is "at least as effective as (i.e. not less effective than)" ramipril 10 mg daily.10 Patients entered a 3-week single-blind run-in before double-blind randomisation.4 Mean blood pressure was lower on telmisartan (0.9/0.6 mm Hg greater reduction) and on the combination (2.4/1.4 mm Hg greater reduction) than on ramipril.4 The rate of syncope was 0.2% in both the telmisartan and ramipril groups; against ramipril, the combination had more hypotensive symptoms (4.8% vs 1.7%), syncope (0.3% vs 0.2%) and renal dysfunction (13.5% vs 10.2%).4 The authors conclude that "Telmisartan was equivalent to ramipril in patients with vascular disease or high-risk diabetes and was associated with less angioedema", and that the combination "was associated with more adverse events without an increase in benefit".4 The registry posts serious adverse events in 5268 of 8502 on the combination, 5506 of 8542 on telmisartan and 5375 of 8576 on ramipril.10 The label says event rates were similar on telmisartan and ramipril, but that the results "did not unequivocally rule out that telmisartan may not preserve a meaningful fraction of the effect of ramipril in reducing cardiovascular events"; its table gives 1423 (16.7%) against 1412 (16.5%), hazard ratio 1.01 with a 97.5% confidence interval of 0.93 to 1.1.1 The label continues that the results of both ONTARGET and TRANSCEND "do adequately support telmisartan being more effective than placebo would be in this setting", and reports that during ONTARGET 22% (n=1878) of telmisartan patients discontinued the active treatment, compared with 24.4% (n=2095) on ramipril and 25.3% (n=2152) on the combination.1 The PubMed record saved for this trial holds a summary only: it carries no funding statement, author disclosures or limitations section, so the authors' own limitations are not reported here.4

Deeper analysis: TRANSCEND

The TRANSCEND Investigators (Yusuf and colleagues) reported the trial in the Lancet in 2008, funded by Boehringer Ingelheim.5 The authors write that ACE inhibitors "are not tolerated by about 20% of patients", which is why the trial enrolled people intolerant to them.5 Mean blood pressure was lower on telmisartan throughout, with a weighted mean difference of 4.0/2.2 mm Hg.5 The primary outcome did not differ significantly (hazard ratio 0.92, 95% CI 0.81-1.05, p=0.216), and one of the secondary outcomes, the composite of cardiovascular death, myocardial infarction or stroke, reached p=0.048 unadjusted but p=0.068 after adjustment for multiplicity.5 Hospitalisation for a cardiovascular reason occurred in 894 (30.3%) on telmisartan and 980 (33.0%) on placebo (relative risk 0.92, 95% CI 0.85-0.99; p=0.025).5 Permanent discontinuation of study medication was 639 (21.6%) on telmisartan and 705 (23.8%) on placebo (p=0.055); the most common reason was hypotensive symptoms, in 29 (0.98%) against 16 (0.54%).5 The authors interpret the trial as follows: "Telmisartan was well tolerated in patients unable to tolerate ACE inhibitors", and although it "had no significant effect on the primary outcome", it "modestly reduced the risk of the composite outcome of cardiovascular death, myocardial infarction, or stroke".5 The label reports discontinuations for adverse events of 8.4% on telmisartan and 7.6% on placebo in TRANSCEND, and serious adverse events at least 1% more common on telmisartan of intermittent claudication (7% vs 6%) and skin ulcer (3% vs 2%).1 The registry posts serious adverse events in 1781 of 2954 on telmisartan and 1830 of 2972 on placebo.10 The PubMed record saved for this trial holds a summary only, with no author disclosures or limitations section, so the authors' own limitations and author ties to the sponsor are not reported here.5

Deeper analysis: Hsueh and colleagues' insulin-sensitivity trial

Hsueh and colleagues, at the Methodist Hospital Research Institute in Houston with sites in the United States, Canada, Germany, Italy and Denmark, reported the trial in the Journal of Clinical Hypertension in 2010; the registry entry NCT00146289 names Boehringer Ingelheim as lead sponsor, with a completed status.3,11 The primary measure was the change from baseline to week 16 in the insulin sensitivity index from a 3-hour oral glucose tolerance test, analysed in the per-protocol set, with a hyperinsulinemic euglycemic clamp in a subset of about 32 patients.3 At 16 weeks the adjusted mean change was 0.30 (SE 0.324) on placebo and 0.19 (SE 0.356) on telmisartan, with no significant difference between groups (difference -0.11; P=.8217).3 Of 138 randomised patients, 128 completed the study; 5 (3.6%) stopped because of adverse events (2 [2.9%] on placebo, 3 [4.3%] on telmisartan), and one telmisartan patient had 2 serious adverse events (pneumonia and diarrhea) that were not considered related to study drug.3 The authors state that "it was not possible to reliably power the study to detect a 20% improvement", that patients were not stratified by insulin resistance, and that the null result could reflect that or "that the available methodology was not sensitive enough to detect small, subclinical effect".3 The authors write that telmisartan at 160 mg/d "was well tolerated in this population of normotensive, nondiabetic patients".3 The disclosures state that the work was supported by Boehringer Ingelheim Pharmaceuticals, that its writing assistance was contracted by the company, that one author (Davidai) is a company employee and that another (Henry) is a member of its advisory board.3 The PubMed records saved for the Wohl, Chetty and Fogari trials hold summary text only, with no funding statements, author disclosures or limitations sections, so those are not reported for them here.6,7,8

5

Doses reported in studies and on labels

These are doses stated on a label or used in named studies, set beside the app's typical range of 20 to 80 mg/day; they are not advice.

Table 5.1Doses reported in studies and on labels9 rows
Source and settingDose and routeComparator, length and nReference
US label, hypertension40 mg orally once daily as the usual starting dose; range 40 to 80 mg once daily; tablets of 20, 40 and 80 mgLabel states blood pressure response is dose-related over 20 to 80 mg; most of the effect apparent within 2 weeks and maximal reduction generally after 4 weeks1
US label, cardiovascular risk reduction80 mg once dailyLabel states it is not known whether doses lower than 80 mg are effective for this use1
ONTARGETTelmisartan 80 mg/day orallyRamipril 10 mg/day, or both; median 56 months; n=25,620 in the label's count4,1
TRANSCENDTelmisartan 80 mg/day orallyPlacebo; median 56 months; n=59265
Hsueh and colleagues80 mg/day for 2 weeks then 160 mg/day for 14 weeks, orallyPlacebo; 16 weeks; n=1383
Wohl and colleagues160 mg/day, orallyPlacebo crossover; 3 weeks each; n=126
Chetty and colleagues80 mg/day for 4 weeks then 160 mg/day, orallyPlacebo; 24 weeks; n=957
Fogari and colleagues80 mg/day, orallyEprosartan 600 mg crossover; 8 weeks each; n=508
Korstanje and colleagues, mice27 ppm telmisartan in the diet, achieved, with 48 ppm atorvastatin (targets 30 and 120 ppm)No telmisartan-alone arm; started at 7 months; 153 male and 132 female treated mice9
6

Side effects reported

Sources in this part

  1. 1Alembic Pharmaceuticals, 2026

The US label states that in placebo-controlled trials of 1041 patients given telmisartan 20 to 160 mg monotherapy for up to 12 weeks, the overall incidence of adverse events was similar to placebo, and that adverse events in hypertension trials were generally "mild and transient in nature".1 Discontinuation because of adverse events was 2.8% of 1455 patients on telmisartan and 6.1% of 380 on placebo in those trials; the most common adverse events at 1% or more in hypertension trials were back pain, sinusitis and diarrhea.1 The label gives the incidence of cough with telmisartan in 6 placebo-controlled trials as identical to placebo (1.6%), and reports a single case of angioedema among 3781 patients in initial clinical studies; postmarketing reports include angioedema with fatal outcome, which the label says came from a population of uncertain size, so frequency and causality cannot always be estimated.1 The boxed warning states that "Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus" and that telmisartan is to be discontinued as soon as pregnancy is detected.1 The label states that hyperkalemia may occur in patients on ARBs, particularly with advanced renal impairment, heart failure, renal replacement therapy, potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium.1 On dual blockade, the label states that combining ARBs, ACE inhibitors or aliskiren "is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy", and that in ONTARGET the combination gave no additional benefit but a higher incidence of renal dysfunction.1

The app lists blood pressure, potassium, creatinine, eGFR, fasting glucose and lipids as markers to monitor; the sources report the following for each.

  • Blood pressure: the label states most of the antihypertensive effect is apparent within 2 weeks and maximal reduction generally after 4 weeks; in TRANSCEND the weighted mean difference from placebo was 4.0/2.2 mm Hg.1,5
  • Potassium: the label's hyperkalemia warning refers to periodic determination of serum electrolytes in patients at risk, while its multiple-dose studies in hypertensive patients reported no clinically significant changes in serum potassium or sodium.1
  • Creatinine and eGFR: a creatinine rise of 0.5 mg/dL or greater occurred in 0.4% on telmisartan and 0.3% on placebo, and in 30 hypertensive patients with normal renal function treated for 8 weeks with telmisartan 80 mg or telmisartan 80 mg with hydrochlorothiazide 12.5 mg the label reports no clinically significant change from baseline in glomerular filtration rate; in ONTARGET renal dysfunction was 13.5% on the combination against 10.2% on ramipril.1,4
  • Fasting glucose: fasting plasma glucose was lower after telmisartan 160 mg/day than placebo in 12 patients with impaired fasting glucose, while Fogari and colleagues report no change in fasting glucose with telmisartan 80 mg/day.6,8
  • Lipids: Fogari and colleagues report total cholesterol -9.9 mg/dl and LDL-C -8.8 mg/dl with telmisartan against placebo, while Hsueh and colleagues report no significant between-group differences in lipoprotein levels and Chetty and colleagues report lipid profiles unaffected.8,3,7
  • The label's pharmacodynamics section states that in multiple dose studies with hypertensive patients there were no clinically significant changes in metabolic function, including serum levels of cholesterol, triglycerides, HDL, LDL and glucose.1

The US label carries a boxed warning for fetal toxicity, and the European product information lists the second and third trimesters of pregnancy among its contraindications.1,2 The text of the WADA 2026 Prohibited List saved for this review has no entry matching telmisartan, "sartan" or "angiotensin".12

The label states that it is not known whether doses lower than 80 mg are effective in reducing the risk of cardiovascular morbidity and mortality.1 The insulin-sensitivity trials compared here ranged from 12 to 138 people and 3 to 24 weeks, and their results do not agree; Hsueh and colleagues call for further studies in a range of populations.6,3,7,8 A search of PubMed for Interventions Testing Program atorvastatin-telmisartan lifespan in mice returned one record, the Korstanje paper; no lifespan study of telmisartan alone in mice was identified in that search, and none in people was sought.9

What is the half-life of telmisartan?

The US label gives telmisartan's terminal elimination half-life as approximately 24 hours, and the app lists 24 hours.1 The European product information gives a terminal elimination half-life of more than 20 hours.2

How long does telmisartan take to reach its peak level?

The US label gives peak concentrations as reached 0.5 to 1 hour after dosing, and the app lists about 1 hour.1

What is the bioavailability of telmisartan?

The US label gives the absolute bioavailability as dose dependent, 42% at 40 mg and 58% at 160 mg, and the app lists 45%.1 The European product information gives a mean absolute bioavailability of about 50%.2

Is telmisartan metabolised by the cytochrome P450 system?

The US label states that the cytochrome P450 isoenzymes are not involved in the metabolism of telmisartan, which is metabolised by conjugation to an inactive acyl glucuronide.1 The label adds that in vitro telmisartan showed some inhibition of CYP2C19.1

Is telmisartan banned by WADA?

The text of the WADA 2026 Prohibited List saved for this review has no entry matching telmisartan.12

What does the boxed warning on telmisartan say?

The US boxed warning is for fetal toxicity: "When pregnancy is detected, discontinue telmisartan as soon as possible".1

What did the ONTARGET trial find?

In ONTARGET, which the label says enrolled 25,620 patients, the primary outcome occurred in 16.7% on telmisartan 80 mg/day and 16.5% on ramipril 10 mg/day (relative risk 1.01, 95% CI 0.94 to 1.09), and the combination was associated with more adverse events without an increase in benefit.4

What did the TRANSCEND trial find?

In 5926 people intolerant to ACE inhibitors, the primary outcome occurred in 15.7% on telmisartan 80 mg/day and 17.0% on placebo (hazard ratio 0.92, 95% CI 0.81-1.05, p=0.216), which was not a significant difference.5

Did telmisartan improve insulin sensitivity in trials?

The trials disagree: Fogari and colleagues report a higher glucose infusion rate on a clamp with telmisartan 80 mg than with placebo in 50 hypertensive patients, while trials of 138, 12 and 95 people report no change in insulin sensitivity.8,3,6,7

Did telmisartan extend lifespan in mice?

The atorvastatin-telmisartan combination did not significantly increase lifespan in male or female UM-HET3 mice in the 2022 cohort of the Interventions Testing Program, and that paper reports no telmisartan-alone arm.9

12

References

  1. Alembic Pharmaceuticals. Telmisartan tablets. US prescribing information (generic telmisartan label), DailyMed record version 11, 2026. DailyMed label
  2. European Medicines Agency. Micardis: summary of product characteristics (EPAR product information). EMA product information
  3. Hsueh W, et al. Telmisartan effects on insulin resistance in obese or overweight adults without diabetes or hypertension. J Clin Hypertens (Greenwich) 2010. PMID 20883237
  4. ONTARGET Investigators, Yusuf S, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008. PMID 18378520
  5. TRANSCEND Investigators, Yusuf S, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008. PMID 18757085
  6. Wohl P, et al. Effect of telmisartan on selected adipokines, insulin sensitivity, and substrate utilization during insulin-stimulated conditions in patients with metabolic syndrome and impaired fasting glucose. Eur J Endocrinol 2010. PMID 20630944
  7. Chetty VT, et al. Metabolic effects of telmisartan in subjects with abdominal obesity: a prospective randomized controlled trial. Blood Press 2014. PMID 23731019
  8. Fogari R, et al. Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients. Horm Metab Res 2009. PMID 19708000
  9. Korstanje R, et al. Astaxanthin, meclizine, mitoglitazone, pioglitazone, alpha-ketoglutarate, mifepristone, methotrexate, and atorvastatin-telmisartan do not increase lifespan in UM-HET3 mice. GeroScience 2026. PMID 41843349
  10. Boehringer Ingelheim. ONTARGET and TRANSCEND. ClinicalTrials.gov entry NCT00153101. NCT00153101
  11. Boehringer Ingelheim. Insulin sensitivity in overweight or obese, non-diabetic, normotensive subjects. ClinicalTrials.gov entry NCT00146289. NCT00146289
  12. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list